Modulation of radiation response by inhibiting topoisomerase II catalytic activity

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 599, Issue 1-2, 2006, Pages 105-115

  Mateos, Santiago ^a   Hajji, Nabil ^a   Pastor, Nuria ^a   Cortés, Felipe ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Aclarubicin; Cytotoxicity; DNA damage; ICRF 193; Radiation; Topoisomerase II inhibitors

Indexed keywords

2,3 BIS(3,5 DIOXO 1 PIPERAZINYL)BUTANE; ACLARUBICIN; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR;

ANIMAL CELL; ARTICLE; CATALYSIS; CELL MUTANT; CELL SURVIVAL; CHINESE HAMSTER; CLONOGENIC ASSAY; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVITY; ENZYME INHIBITION; IRRADIATION; KINETOPLAST; MOLECULAR INTERACTION; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; RADIATION RESPONSE; RADIOSENSITIVITY;

ACLARUBICIN; ANIMALS; CELL LINE; CELL SURVIVAL; CRICETINAE; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DNA, KINETOPLAST; ENZYME INHIBITORS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MUTATION; NEOPLASMS; PHOSPHOPROTEINS; PIPERAZINES; RADIATION TOLERANCE;

CRICETULUS GRISEUS;

EID: 33745913023     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2006.02.002     Document Type: Article

References (55)

1. Emami B., Lyman J., Brown A., Coia L., Goitein M., Munzenrider J.E., Shank B., Solin L.J., and Wesson M. Tolerance of normal tissue to therapeutic irradiation. Int. J. Radiat. Oncol. Biol. Phys 21 (1991) 109-122
2. Dörr W., and Hendry J.H. Consequential late effects in normal tissues. Radiother. Oncol. 61 (2001) 223-231
3. Denham J.W., Hauer-Jensen M., and Peters L.J. Is it time for a new formalism to categorize normal tissue radiation injury?. Int. J. Radiat. Oncol. Biol. Phys. 50 (2001) 105-106
4. Boorstein R.J., and Pardee A.B. Beta-lapachone greatly enhances MMS lethality to human fibroblasts. Biochem. Biophys. Res. Commun. 118 (1984) 828-834
5. Li J.Q., and Pardee A.B. Enhanced lethality to human breast cancer cells of neocarcinostatin by camptothecin and beta-lapachone, a novel DNA topoisomerase I modulator with a different mode of action from camptothecin. Proceedings of the Annual Meeting of American Association for Cancer Research, vol. 3 (1992) 2583a
6. Mattern M.R., Hofmann G.A., McCabe F.L., and Johnson R.K. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). Cancer Res. 51 (1991) 5813-5816
7. Boothman D.A., Wang M., Schea R.A., Burrows H.L., Strickfaden S., and Owens J.K. Posttreatment exposure to camptothecin enhances the lethal effects of X-rays on radioresistant human malignant melanoma cells. Int. J. Radiat. Oncol. Biol. Phys. 24 (1992) 939-948
8. Andoh T., and Ishida R. Catalytic inhibitors of DNA topoisomerase II. Biochim. Biophys. Acta 1400 (1998) 155-171
9. Liu L.F. DNA topoisomerase poisons as antitumor drugs. Ann. Rev. Biochem. 58 (1989) 351-375
10. Roca J., Ishida R., Berger J.M., Andoh T., and Wang J.C. Antitumor bis-dioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc. Natl. Acad. Sci. USA 91 (1994) 1781-1785
11. Hansen O.P., Pedersen-Bjergaard J., Ellegaard J., Brincher H., Boesen A.M., Christensen B.E., Drivsholm A., Hippe E., Jans H., Jensen K.B., et al. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. Leukemia 5 (1991) 510-516
12. Meyn M.S. Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene. Clin. Genet. 55 (1999) 289-304
13. Thacker J., and Ganesh A.N. DNA break repair radioresistance of DNA synthesis and camptothecin sensitivity in the radiation-sensitive irs mutants: comparisons to ataxia-telangiectasia cells. Mutat. Res. 235 (1990) 49-58
14. Jones N.J., Ellard S., Waters R., and Parry E.M. Cellular and chromosomal hypersensitivity to DNA crosslinking agents and topoisomerase inhibitors in the radiosensitive Chinese hamster irs mutants: phenotypic similarities to ataxia telangiectasia and fanconi's anemia cells. Carcinogenesis 14 (1993) 2487-2494
15. Heartlein M.W., Tsuji H., and Latt S.A. 5-bromo-deoxyuridine-dependent increase in sister chromatid exchange formation in Bloom's syndrome is associated with reduction in topoisomerase II activity. Exp. Cell Res. 169 (1987) 245-254
16. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
17. Singh N.P., McCoy M.T., Tice R.R., and Schneider E.L. A simple technique for quantification of low levels of DNA damage in individual cells. Exp. Cell Res. 175 (1988) 184-191
18. Fairbain D.W., Olive P.L., and O'Neill K.L. The comet assay: a comprehensive review. Mutat. Res. 339 (1995) 37-59
19. Olive P.L., Banath J.P., and Durand R.E. Detection of etoposide resistance by measuring DNA damage in individual Chinese hamster cells. J. Natl. Cancer Inst. 82 (1990) 779-783
20. In: DeVita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: Principle and Practice of Oncology. 6th ed. (2001), J.B. Lippincott, Philadelphia
21. Hall E.J. Radiobiology for the radiologist. 5th ed. (2000), J.B. Lippincott, Philadelphia
22. In: John M., Flam M., Legha S., and Phillips T. (Eds). Chemoradiation: An Integrated Approach to Cancer Treatment. 1st ed. (1995), J.B. Lippincott, Philadelphia
23. McGinn C.J., Shewach D.S., and Lawrence T.S. Radiosensitizing nucleotides. J. Natl. Cancer Inst. 88 (1996) 1193-1203
24. Kim J.H., Kim S.H., Kolozsvary A., and Khil M.S. Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I. Int. J. Radiat. Oncol. Biol. Phys. 22 (1992) 515-518
25. Barret J.M., Hill B., and Olive P.L. Characterization of DNA-strand breakage induced in V79 cells by F11782, a catalytic inhibitor of topoisomerases. Br. J. Cancer 83 (2000) 1740-1746
26. Barret J.M., Montaudon D., Etiévant C., Perrin D., Kruczynski A., Robert J., and Hill B.T. Detection of DNA-strand breaks in cells treated with F11782, a catalytic inhibitor of topoisomerases I and II. Anticancer Res. 20 (2000) 4557-4562
27. Barret J.M., Kruczynski A., Etiévant C., and Hill B.T. Synergistic effects of F11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents. Cancer Chemother. Pharmacol. 49 (2002) 479-486
28. Chou T.C., Motzer R.J., Tong Y., and Bosl G.J. Computerized quantitation of synergism and antagonism of Taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J. Natl. Cancer Inst. 86 (1994) 1517-1524
29. Kaufmann S.H., Peereboom D., Buckwalter C.A., Svingen P.A., Grochow L.B., Donehower R.C., and Rowinsky E.K. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J. Natl. Cancer Inst. 88 (1996) 734-741
30. Kano Y., Akutsu M., Tsunoda S., Mori K., Suzuki K., and Adachi K.I. In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines. Cancer Chemother. Pharmacol. 42 (1998) 91-98
31. Ma J., Maliepaard M., Nooter K., Boersma A.W., Vermeij J., Stoter G., and Schellens J.H. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother. Pharmacol. 41 4 (1998) 307-316
32. Perez E.A., and Buckwalter C.A. Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines. Cancer Chemother. Pharmacol. 41 6 (1998) 448-452
33. Frankenberg D., Frankenberg-Schwager M., Blocher D., and Harbich R. Evidence for DNA double-strand breaks as the critical lesions in yeast cells irradiated with sparsely or densely ionizing radiation under oxic or anoxic conditions. Radiat. Res. 88 (1981) 524-532
34. McMillan T.J., Tobi S., Mateos S., and Lemon C. The use of DNA double-strand break quantification in radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 49 (2001) 373-377
35. Tanabe K., Ikegami Y., Ishida R., and Andoh T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine)9 derivates. Cancer Res. 51 (1991) 4903-4908
36. Hajji N., Pastor N., Mateos S., Domínguez I., and Cortés F. DNA strand breaks induced by the anti-topoisomerase II bis-dioxopiperazine ICRF-193. Mutat. Res. 530 (2003) 35-46
37. Bridewell D.J.A., Finlay G.J., and Baguley B.C. Differential actions of aclarubicin and doxorubicin: the role of topoisomerase I. Oncol. Res. 9 (1997) 535-542
38. Nitiss J.L., Pourquier P., Pommier Y., and Aclacinomycin. A stabilizes topoisomerase I covalent complexes. Cancer Res. 57 (1997) 4564-4569
39. Hajji N., Mateos S., Pastor N., Domínguez I., and Cortés F. Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor. Mutat. Res. 583 (2005) 26-35
40. Hsiang Y.H., Hertzberg R., Hecht S., and Liu L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260 (1985) 14873-14878
41. Hsiang Y.H., and Liu L.F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 48 (1998) 1722-1726
42. Froelich-Ammon S.J., and Osheroff N. Topoisomerse poisons-harnessing the dark side of enzyme mechanism. J. Biol. Chem. 270 (1995) 21429-21432
43. Chen A.Y., Okunieff P., Pommier Y., and Mitchell J.B. Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives. Cancer Res. 57 (1997) 1529-1536
44. Boothman D.A., Wang M., Schea R.A., Burrows H.L., Strickfaden S., and Owens J.K. Posttreatment exposure to camptothecin enhances the lethal effects of X-rays on radioresistant human malignant melanoma cells. Int. J. Radiat. Oncol. Biol. Phys. 24 (1992) 939-948
45. Kirichenko A.V., Rich T.A., Newman R.A., and Travis E.L. Potentiation of murine MCa-4 carcinoma radioresponse by 9-amino-20(S)-camptothecin. Cancer. Res. 57 (1997) 1929-1933
46. Kim J.S., Amorino G.P., Pyo H., Cao Q., and Choy H. Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells. Radiother. Oncol. 62 (2002) 61-67
47. Johnson M.A., Bryant P.E., and Jones N.J. Isolation of camptothecin-sensitive Chinese hamster cell mutants: phenotypic heterogeneity within the ataxia telangiectasia-like XRCC8 (irs2) complementation group. Mutagenesis 4 (2000) 367-374
48. Jones N.J., Stewart S.A., and Thompson L.H. Biochemical and genetic analysis of the Chinese hamster mutants irs1 and irs2 and their comparison to cultured ataxia telangiectasia cells. Mutagenesis 5 (1990) 15-23
49. Xu B., Kim S.T., Lim D.S., and Kastan M.B. Two molecularly distinct G(2)/M checkpoints are induced by ionizing irradiation. Mol. Cell Biol. 22 (2002) 1049-1059
50. Ree A.H., Bratland A., Nome R.V., Stokke T., Fodstad O., and Andersson Y. Inhibitory targeting of checkpoint kinase signaling overrides radiation-induced cell cycle gene regulation: a therapeutic strategy in tumor cell radiosensitization?. Radiother. Oncol. 72 3 (2004) 305-310
51. Iliakis G., Wang Y., Guan J., and Wang H. DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene 22 (2003) 5834-5847
52. Nitiss J.L. DNA topoisomerases in DNA repair and DNA damage tolerance. In: Nicoloff J.A., and Hoekstra M.F. (Eds). DNA Damage and Repair (1998), Humana Press, Totowa 517-538
53. Gaffney D.K., Lundquist M., Warters R.L., and Rosley R. Effects of modifying topoisomerase II levels on cellular recovery from radiation damage. Radiat. Res. 154 (2000) 461-466
54. Maeshima K., and Laemmli U.K. A two-step scaffolding model for mitotic chromosome assembly. Dev. Cell 4 (2003) 467-480
55. Pastor N., and Cortés F. Bufalin influences the repair of X-ray-induced DNA breaks in Chinese hamster cells. DNA Repair 2 (2003) 1353-1360